After the 2025 American Society of Hematology Annual Meeting, experts reviewed key data and discussed practice implications in an X Spaces session hosted by CancerNetwork in collaboration with the American Society for Transplantation and Cellular Therapy.
Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, highlighted results from the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed or refractory multiple myeloma who had progressed after at least one prior line of therapy. The combination reportedly produced a significant progression-free survival benefit versus standard of care.
They also reviewed cohort A data from the phase 2 IFM2021-01 trial (NCT05572229), which tested subcutaneous teclistamab combined with subcutaneous daratumumab in newly diagnosed, transplant-ineligible patients. The investigators reported that the regimen was effective and had an acceptable safety profile in the frontline setting.
The discussion compared bispecific antibodies with BCMA-directed CAR T-cell therapies, explored frontline bispecific strategies for transplant-ineligible populations, and considered the role of bispecifics as post-transplant consolidation. Panelists said multiple myeloma care is shifting toward deeper minimal residual disease negativity, potential treatment de-escalation, and even use of the term “cure” in selected contexts.
Banerjee is an assistant professor in the Clinical Research Division at Fred Hutchinson Cancer Center. Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both serve on the ASTCT content committee.
Leave a Reply